CELZ Expands ADAPT Trial
Creative Medical Technology Holdings expands ADAPT trial under new FDA clearance and advances toward Phase 3 planning for Olastrocel in chronic lower back pain
CELZ - Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain